In a move that could eventually make weight loss drugs cheaper and easier to access, the Food and Drug Administration Monday approved a second generic in the category of medications known as GLP-1s.

Sandoz US to pay USD 265 million in exchange for full release of all claims by the class Resolves all federal antitrust damages for direct purchaser class plaintiffs’ claims in this litigation, if ...

Sandoz US has entered into a settlement agreement with the class of end payer plaintiffs for USD 275 million Provision of USD 265 million taken to cover potential additional settlement costs with ...

Generic use has increased over time in Medicare Part D, but substantial variation across plans persists in a number of common classes. Objectives: The use of generics in Medicare Part D generates cost ...

Indivior, a pharmaceutical company, has reached a $30 million settlement to resolve a class action lawsuit filed in a U.S. court by health plans. The lawsuit alleges that the company unlawfully ...

Sandoz has announced a number of steps to resolve the US Generic Drug Antitrust Class Action Litigation. Following the previously announced settlements with the U.S. Department of Justice in 2020 and ...